Toxicity Profile of Double-agent Adjuvant Chemotherapy after Concurrent Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer: Comparison with Standard Chemoradiation Protocol

Tejas Pandya; Virender Suhag; Subhash Ranjan; BS Sunita; Sujata Pandya

doi:10.4103/ijmpo.ijmpo_171_17

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(S 01): S6-S12
DOI: 10.4103/ijmpo.ijmpo_171_17

Original Article

Toxicity Profile of Double-agent Adjuvant Chemotherapy after Concurrent Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer: Comparison with Standard Chemoradiation Protocol

Tejas Pandya

Departments of Radiotherapy, ECHS Polyclinic, Base Hospital, New Delhi, India

,

Virender Suhag

Departments of Radiotherapy, ECHS Polyclinic, Base Hospital, New Delhi, India

,

Subhash Ranjan

Departments of Radiotherapy, ECHS Polyclinic, Base Hospital, New Delhi, India

,

BS Sunita

Departments of Pathology, Army Hospital (R and R), ECHS Polyclinic, Base Hospital, New Delhi, India

,

Sujata Pandya

Departments of Medical Officer Gynaecology, ECHS Polyclinic, Base Hospital, New Delhi, India

› Author Affiliations

Abstract

Introduction: Carcinoma cervix is the most common gynecological malignancy in India and a major cause of cancer mortality and morbidity in the females despite Concurrent chemoradiotherapy (CCRT). Attempts are on to improved overall survival by addition of adjuvant chemotherapy (ACT) to CCRT. Aim: The aim of this study is to establish toxicity profile of double-agent ACT after CCRT and ICRT in locally advanced cervical cancer (LACC) and to compare it with standard chemoradiation protocol. Materials and Methods: Patients were randomized into two arms: in conventional arm (Arm 1, n = 23), patients received a standard protocol of weekly injection cisplatin 40 mg/m² concurrently with pelvic external beam radiotherapy (5040cGy/28 fractions) followed by ICRT (03 fractions of 7 Gy each). In interventional arm (Arm 2, n = 24), patients received CCRT/ICRT protocol; and were further offered ACT with three cycles of consolidation chemotherapy using injection paclitaxel and injection carboplatin every 3 weeks after CCRT and ICRT. Results: The incidence of anemia was 14/23 (50% Grade 1) in Arm 1 and 12/24 in Arm 2 (17% Grade 1, rest higher grade). In Arm 2, 37% of patients had ≥Grade 2 neuropathy and 16% of patients had Grade 1 alopecia, whereas nil incidence was reported in Arm 1 (P = 0.005 and 0.04, respectively). Grade 3 neutropenia was observed in 4/23 (17%) patients of Arm 1 and 8/24 patients (33%) of Arm 2. None of the patients in Arm 1 required indoor supportive care while 4/24 patients (17%) were managed as an indoor patient. Among late toxicities, in Arm 2, the incidence of Grade 2 and Grade 3 anemia was 42%, whereas in Arm 1, its incidence was 22%. In Arm 1, no patient exhibited features of neuropathy, whereas, in Arm 2, 12/24 (50%) of the patients had neuropathy (P value for these two late events was <0.05 statistically significant). No therapy-induced mortality was noted. Conclusion: Exhibition of ACT with injection Paclitaxel and injection carboplatin in locally advanced carcinoma cervix is a technically viable option with manageable toxicity.

Keywords

Acute toxicities - adjuvant chemotherapy - concurrent chemoradiation therapy - delayed toxicities - locally advanced cancer cervix

Full Text

References

References
1 Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B. et al. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev 2014; 12: CD010401
2 Varghese SS, Ram TS, Pavamani SP, Thomas EM, Jeyaseelan V, Viswanathan PN. et al. Concurrent chemo-irradiation with weekly cisplatin and paclitaxel in the treatment of locally advanced squamous cell carcinoma of cervix: A phase II study. J Cancer Res Ther 2014; 10: 330-6
3 Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY. et al. Advances and concepts in cervical cancer trials: A Road map for the future. Int J Gynecol Cancer 2016; 26: 199-207
4 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. [Last accessed on 2017 May 12].
5 Singh JK, Chauhan R. Management of locally advanced cancer cervix an Indian perspective. Rev Recent Clin Trials 2015; 10: 298-301
6 Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol 2016; 37: 278-85
7 Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. Int J Womens Health 2015; 7: 405-14
8 Asano H, Todo Y, Watari H. Adjuvant chemotherapy for early-stage cervical cancer. Chin J Cancer Res 2016; 28: 228-34
9 Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J. et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 2004; 22: 3113-9
10 Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of cheoradiotherapy for cervical cancer: Individual patient data meta-analysis. Cochrane Database Syst Rev 2010; 1: CD008285
11 Mitra D, Ghosh B, Kar A, Basu S, Deb AR, Sur PK. et al. Role of chemoradiotherapy in advanced carcinoma cervix. J Indian Med Assoc 2006; 104: 432, 434, 436
12 Zarbá JJ, Verma J, Monk BJ, Wolfson AH. New strategies for multimodality therapy in treating locally advanced cervix cancer. Semin Radiat Oncol 2016; 26: 344-8
13 Jelavić TB, Miše BP, Strikic A, Ban M, Vrdoljak E. Adjuvant chemotherapy in locally advanced cervical cancer after treatment with concomitant chemoradiotherapy – Room for improvement?. Anticancer Res 2015; 35: 4161-5
14 Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L. et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005; 3: CD002225
15 Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J. et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22: 872-80
16 Singh U, Ahirwar N, Rani AK, Singh N, Sankhwar P, Qureshi S. et al. The efficacy and safety of neoadjuvant chemotherapy in treatment of locally advanced carcinoma cervix. J Obstet Gynaecol India 2013; 63: 273-8
17 Vrdoljak E, Omrcen T, Novaković ZS, Jelavić TB, Prskalo T, Hrepić D. et al. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix – Final results of a prospective phase II-study. Gynecol Oncol 2006; 103: 494-9
18 Zhang MQ, Liu SP, Wang XE. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: Preliminary results of a phase II study. Int J Radiat Oncol Biol Phys 2010; 78: 821-7
19 Choi IJ, Cha MS, Park ES, Han MS, Choi Y, Je GH. et al. The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. J Gynecol Oncol 2008; 19: 129-34
20 Domingo E, Lorvidhaya V, de Los Reyes R, Syortin T, Kamnerdsupaphon P, Lertbutsayanukul C. et al. Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: Phase II results. Oncologist 2009; 14: 828-34
21 Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008; 26: 5802-12
22 Ali N, Valimohammad AT, Abbasi AN, Mansha MA, Asim Hafiz A, Qureshi BM. Chemoradiation and the role of adjuvant chemotherapy in lymph nodal – Metastatic cervical cancer. J Glob Oncol 2017; Published online on jgo.org on 2017:1-4. Available from:https://doi.org/10.1200/JGO.2017.009852. [Last accessed on 2017 May 12].
23 Abe A, Furumoto H, Nishimura M, Irahara M, Ikushima H. Adjuvant chemotherapy following concurrent chemoradiotherapy for uterine cervical cancer with lymphadenopathy. Oncol Lett 2012; 3: 571-6
24 Tang J, Tang Y, Yang J, Huang S. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol Oncol 2012; 125: 297-302
25 Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L. et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011; 29: 1678-85
26 Lorvidhaya V, Chitapanarux I, Sangruchi S, Lertsanguansinchai P, Kongthanarat Y, Tangkaratt S. et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: A randomized trial. Int J Radiat Oncol Biol Phys 2003; 55: 1226-32
27 Sangkittipaiboon S. Long-term outcomes of concurrent chemoradiotherapy with weekly carboplatin in locally-advanced carcinoma of the uterine cervix patients. J Med Assoc Thai 2014; 97: 12-9
28 McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V. et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer 2013; 108: 2464-9